Kamal M. El-Gamal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kamal M. El-Gamal has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Hamada S. Abulkhair
Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Al-Azhar University, Nasr City, 11884, Cairo, Egypt
2 shared publications Ahmed A. Gaber
Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy Al‐Azhar University Cairo Nasr City Egypt
1 shared publication- Ahmed Ali Al-Karmalawy
Department of Pharmaceutical Chemistry, College of Pharmacy The University of Mashreq Baghdad Iraq
1 shared publication - Ahmed M. El-Morsy
Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, Cairo 11884, Egypt
1 shared publication - Ashraf H. Bayoumi
Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy Al‐Azhar University Cairo Nasr City Egypt
1 shared publication Farag F. Sherbiny
Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy Al‐Azhar University Cairo Nasr City Egypt
1 shared publication
Latest Publications
- 31 August 2021
- Published by Wiley in Archiv der Pharmazie
- Vol. 358 (3) , e2100258
Pharmacophore‐linked pyrazolo[3,4‐d]pyrimidines as EGFR‐TK inhibitors: Synthesis, anticancer evaluation, pharmacokinetics, and in silico mechanistic studies
Targeting the epidermal growth factor receptors (EGFRs) with small inhibitor molecules has been validated as a potential therapeutic strategy in cancer therapy. Pyrazolo[3,4‐d]pyrimidine is a versatile scaffold that has been exploited for developing potential anticancer agents. On the basis of fragment‐based drug discovery, considering the essential pharmacophoric features of potent EGFR tyrosine kinase (TK) inhibitors, herein, we report the design and synthesis of new hybrid molecules of the pyrazolo[3,4‐d]pyrimidine scaffold linked with diverse pharmacophoric fragments with reported anticancer potential. These fragments include hydrazone, indoline‐2‐one, phthalimide, thiourea, oxadiazole, pyrazole, and dihydropyrazole. The synthesized molecules were evaluated for their anticancer activity against the human breast cancer cell line, MCF‐7. The obtained results revealed comparable antitumor activity with that of the reference drugs doxorubicin and toceranib. Docking studies were performed along with EGFR‐TK and ADMET profiling studies. The results of the docking studies showed the ability of the designed compounds to interact with key residues of the EGFR‐TK through a number of covalent and noncovalent interactions. The obtained activity of compound 25 (IC50 = 2.89 µM) suggested that it may serve as a lead for further optimization and drug development.
- 31 August 2021
- Published by Wiley in Archiv der Pharmazie
- Vol. 358 (3) , e2100258
Pharmacophore‐linked pyrazolo[3,4‐d]pyrimidines as EGFR‐TK inhibitors: Synthesis, anticancer evaluation, pharmacokinetics, and in silico mechanistic studies
Targeting the epidermal growth factor receptors (EGFRs) with small inhibitor molecules has been validated as a potential therapeutic strategy in cancer therapy. Pyrazolo[3,4‐d]pyrimidine is a versatile scaffold that has been exploited for developing potential anticancer agents. On the basis of fragment‐based drug discovery, considering the essential pharmacophoric features of potent EGFR tyrosine kinase (TK) inhibitors, herein, we report the design and synthesis of new hybrid molecules of the pyrazolo[3,4‐d]pyrimidine scaffold linked with diverse pharmacophoric fragments with reported anticancer potential. These fragments include hydrazone, indoline‐2‐one, phthalimide, thiourea, oxadiazole, pyrazole, and dihydropyrazole. The synthesized molecules were evaluated for their anticancer activity against the human breast cancer cell line, MCF‐7. The obtained results revealed comparable antitumor activity with that of the reference drugs doxorubicin and toceranib. Docking studies were performed along with EGFR‐TK and ADMET profiling studies. The results of the docking studies showed the ability of the designed compounds to interact with key residues of the EGFR‐TK through a number of covalent and noncovalent interactions. The obtained activity of compound 25 (IC50 = 2.89 µM) suggested that it may serve as a lead for further optimization and drug development.
- Open Access
- 28 August 2016
- Published by Faculty of Pharmacy Cairo University in Bulletin of Faculty of Pharmacy, Cairo University
- Vol. 54 (2) , 263-273
Synthesis, characterization and antimicrobial evaluation of some novel quinoline derivatives bearing different heterocyclic moieties
A series of 3-substituted 6-methoxy-1H-pyrazolo [3,4-b]quinoline derivatives was synthesized by treating 6-methoxy-1H-pyrazolo[3,4-b]quinolin-3-amine (6) with different acid anhydrides including succinic anhydride, maleic anhydride and phthalic anhydride. Also, a series of 3-heteroaryl-2-chloro-6-methoxyquinolines was prepared through 1,3-dipolar cycloaddition of different bi-nucleophiles including hydrazine hydrate, hydroxylamine hydrochloride, thiourea, guanidine hydrochloride, urea and metformin hydrochloride to the chalcone derivative 3-(2-chloro-6-methoxyquinolin-3-yl)-1-(4-methoxyphenyl)prop-2-en-1-one. Structural identifications of all products were reported and the new compounds were screened for their in vitro antimicrobial activity against Streptococcus pneumonia and Bacillus subtilis as examples for Gram-positive bacteria, Pseudomonas aeruginosa and Escherichia coli as examples for Gram-negative bacteria, and Aspergillus fumigatus, Syncephalastrum racemosum, Geotriucum candidum and Candida albicans as representative examples of fungi. The majority of tested compounds showed moderate activities against a wide range of the selected organisms. Among the tested compounds, pyrimidine derivatives 16 and 17 showed the highest antimicrobial activity against gram-positive strains while the highest activity against E. coli as example for Gram-negative strains was observed in the case of 11 and 17. Compounds 14 and 17 were found to be extremely potent against three of the selected fungal strains.
- 28 August 2016
- Published by Faculty of Pharmacy Cairo University in Bulletin of Faculty of Pharmacy, Cairo University
- Vol. 54 (2) , 263-273
Open AccessSynthesis, characterization and antimicrobial evaluation of some novel quinoline derivatives bearing different heterocyclic moieties
A series of 3-substituted 6-methoxy-1H-pyrazolo [3,4-b]quinoline derivatives was synthesized by treating 6-methoxy-1H-pyrazolo[3,4-b]quinolin-3-amine (6) with different acid anhydrides including succinic anhydride, maleic anhydride and phthalic anhydride. Also, a series of 3-heteroaryl-2-chloro-6-methoxyquinolines was prepared through 1,3-dipolar cycloaddition of different bi-nucleophiles including hydrazine hydrate, hydroxylamine hydrochloride, thiourea, guanidine hydrochloride, urea and metformin hydrochloride to the chalcone derivative 3-(2-chloro-6-methoxyquinolin-3-yl)-1-(4-methoxyphenyl)prop-2-en-1-one. Structural identifications of all products were reported and the new compounds were screened for their in vitro antimicrobial activity against Streptococcus pneumonia and Bacillus subtilis as examples for Gram-positive bacteria, Pseudomonas aeruginosa and Escherichia coli as examples for Gram-negative bacteria, and Aspergillus fumigatus, Syncephalastrum racemosum, Geotriucum candidum and Candida albicans as representative examples of fungi. The majority of tested compounds showed moderate activities against a wide range of the selected organisms. Among the tested compounds, pyrimidine derivatives 16 and 17 showed the highest antimicrobial activity against gram-positive strains while the highest activity against E. coli as example for Gram-negative strains was observed in the case of 11 and 17. Compounds 14 and 17 were found to be extremely potent against three of the selected fungal strains.